Peter Hellemans

1.9k total citations
57 papers, 1.4k citations indexed

About

Peter Hellemans is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Peter Hellemans has authored 57 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 21 papers in Molecular Biology and 18 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Peter Hellemans's work include Chronic Lymphocytic Leukemia Research (14 papers), Multiple Myeloma Research and Treatments (14 papers) and Monoclonal and Polyclonal Antibodies Research (11 papers). Peter Hellemans is often cited by papers focused on Chronic Lymphocytic Leukemia Research (14 papers), Multiple Myeloma Research and Treatments (14 papers) and Monoclonal and Polyclonal Antibodies Research (11 papers). Peter Hellemans collaborates with scholars based in Belgium, United States and Spain. Peter Hellemans's co-authors include A.T. van Oosterom, P. Buytaert, Johan W. Smit, Joost Weyler, Eric Van Marck, Jan Gerris, Juthamas Sukbuntherng, Ronald de Vries, Jan de Jong and Petra Verdonk and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Peter Hellemans

56 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Hellemans Belgium	20	552	533	381	363	272	57	1.4k
Alberto Bessudo United States	18	517 0.9×	609 1.1×	258 0.7×	359 1.0×	388 1.4×	70	1.2k
Francesco Turturro United States	19	580 1.1×	637 1.2×	253 0.7×	546 1.5×	412 1.5×	64	1.4k
Vincent Ribrag France	19	505 0.9×	907 1.7×	382 1.0×	854 2.4×	282 1.0×	80	1.9k
Jean Powers Canada	17	561 1.0×	556 1.0×	270 0.7×	356 1.0×	132 0.5×	32	1.3k
Alan Barge United Kingdom	14	411 0.7×	819 1.5×	183 0.5×	179 0.5×	664 2.4×	21	1.5k
Massimo Gentile Italy	25	820 1.5×	593 1.1×	898 2.4×	640 1.8×	665 2.4×	177	2.1k
Jon Holmlund United States	24	1.1k 2.0×	537 1.0×	126 0.3×	164 0.5×	128 0.5×	55	1.7k
K. C. Anderson United States	20	670 1.2×	440 0.8×	206 0.5×	191 0.5×	622 2.3×	38	1.6k
Virginia E. Kwitkowski United States	16	484 0.9×	423 0.8×	108 0.3×	192 0.5×	119 0.4×	18	1.2k
Howard Fingert United States	23	765 1.4×	1.1k 2.0×	134 0.4×	169 0.5×	135 0.5×	47	1.9k

Countries citing papers authored by Peter Hellemans

Since Specialization

Citations

This map shows the geographic impact of Peter Hellemans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Hellemans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Hellemans more than expected).

Fields of papers citing papers by Peter Hellemans

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Hellemans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Hellemans. The network helps show where Peter Hellemans may publish in the future.

Co-authorship network of co-authors of Peter Hellemans

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Hellemans. A scholar is included among the top collaborators of Peter Hellemans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Hellemans. Peter Hellemans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yu, Alex, Anasuya Hazra, James Jiao, et al.. (2024). Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation. Clinical Pharmacokinetics. 63(4). 511–527. 1 indexed citations

Moreno, Víctor, Ruth Perets, Nele Fourneau, et al.. (2022). A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors. Investigational New Drugs. 41(1). 93–104. 18 indexed citations

Krebs, Matthew, Melissa L. Johnson, Byoung Chul Cho, et al.. (2021). Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: PALOMA, an open-label, multicenter, dose escalation phase 1b study.. Journal of Clinical Oncology. 39(15_suppl). TPS3150–TPS3150. 3 indexed citations

Posadas, Edwin M., Kim N., Ronald de Wit, et al.. (2020). Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study. Clinical Cancer Research. 26(14). 3517–3524. 12 indexed citations

Miguel, Jesús F. San, Saad Z. Usmani, María‐Victoria Mateos, et al.. (2020). Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO). Haematologica. 106(6). 1725–1732. 25 indexed citations

Jong, Jan de, Nahor Haddish‐Berhane, Peter Hellemans, et al.. (2018). The pH-altering agent omeprazole affects rate but not the extent of ibrutinib exposure. Cancer Chemotherapy and Pharmacology. 82(2). 299–308. 8 indexed citations

Jong, Jan de, Peter Hellemans, James Jiao, et al.. (2017). Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study. Cancer Chemotherapy and Pharmacology. 80(6). 1227–1237. 22 indexed citations

Moreau, Philippe, Thierry Façon, Cyrille Touzeau, et al.. (2016). Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma. Leukemia & lymphoma. 57(7). 1546–1559. 24 indexed citations

Jong, Jan de, Donna Skee, Peter Hellemans, et al.. (2016). Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment^*. Leukemia & lymphoma. 58(1). 185–194. 17 indexed citations

10.

Lolkema, Martijn P., Hilde Bohets, Hendrik‐Tobias Arkenau, et al.. (2015). The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation. Clinical Cancer Research. 21(10). 2297–2304. 68 indexed citations

11.

Jong, Jan de, Juthamas Sukbuntherng, Donna Skee, et al.. (2015). The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia. Cancer Chemotherapy and Pharmacology. 75(5). 907–916. 60 indexed citations

12.

Younes, Anas, Catherine Thiéblemont, Franck Morschhauser, et al.. (2014). Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. The Lancet Oncology. 15(9). 1019–1026. 186 indexed citations

13.

Venugopal, Balaji, Richard D. Baird, Rebecca Kristeleit, et al.. (2013). A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 19(15). 4262–4272. 97 indexed citations

14.

Baird, Richard D., B. Venugopal, Montserrat Blanco-Codesido, et al.. (2011). A first-in-human phase I study of JNJ-26481585, a novel oral histone deacetylase inhibitor (HDACi), in patients with advanced cancer with evidence of target modulation and antitumor activity.. Journal of Clinical Oncology. 29(15_suppl). 3024–3024. 1 indexed citations

15.

Konings, Inge R., Maja J.A. de Jonge, Henry Burger, et al.. (2010). Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours. British Journal of Cancer. 103(7). 987–992. 17 indexed citations

16.

Scalliet, Pierre, Christel De Pooter, Peter Hellemans, E. A. de Bruijn, & A.T. van Oosterom. (1999). Interactions entre le carboplatine, le cisplatine et les rayonnements ionisants dans une lignée cellulaire humaine de cancer ovarien. Cancer/Radiothérapie. 3(1). 30–38. 7 indexed citations

17.

Hellemans, Peter, et al.. (1995). Prognostic value of bcl-2 expression in invasive breast cancer. British Journal of Cancer. 72(2). 354–360. 166 indexed citations

18.

Hellemans, Peter, Jan Gerris, & Petra Verdonk. (1995). Fetal fibronectin detection for prediction of preterm birth in low risk women. BJOG An International Journal of Obstetrics & Gynaecology. 102(3). 207–212. 62 indexed citations

19.

Hellemans, Peter, et al.. (1992). Preliminary results with the use of the ROM-check immunoassay in the early detection of rupture of the amniotic membranes. European Journal of Obstetrics & Gynecology and Reproductive Biology. 43(3). 173–179. 12 indexed citations

20.

Gerris, Jan, et al.. (1991). Placebo-controlled trial of high-dose Mesterolone treatment of idiopathic male infertility. Fertility and Sterility. 55(3). 603–607. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact